Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $974.0 million.

  • Arcus Biosciences' Liabilities and Shareholders Equity fell 2507.69% to $974.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year decrease of 1103.17%. This contributed to the annual value of $1.2 billion for FY2024, which is 502.28% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Liabilities and Shareholders Equity is $974.0 million, which was down 2507.69% from $1.1 billion recorded in Q2 2025.
  • Arcus Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $1.6 billion during Q4 2021, with a 5-year trough of $839.3 million in Q3 2021.
  • In the last 5 years, Arcus Biosciences' Liabilities and Shareholders Equity had a median value of $1.2 billion in 2024 and averaged $1.2 billion.
  • In the last 5 years, Arcus Biosciences' Liabilities and Shareholders Equity soared by 43088.33% in 2021 and then tumbled by 2507.69% in 2025.
  • Over the past 5 years, Arcus Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $1.6 billion in 2021, then dropped by 18.34% to $1.3 billion in 2022, then decreased by 15.77% to $1.1 billion in 2023, then increased by 5.02% to $1.2 billion in 2024, then decreased by 15.3% to $974.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $974.0 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.2 billion in Q1 2025.